RecruitingPhase 2NCT07311408

SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure

SHR-1701 Combined With Rivoceranib, With or Without SHR-2554, in Patients With Advanced Gastric Cancer Who Have Failed First-Line Immunotherapy

Sponsor

Jingdong Zhang

Enrollment

40 participants

Start Date

Jan 1, 2026

Study Type

INTERVENTIONAL

Conditions

Gastroesophageal Junction Adenocarcinoma Gastric Cancer (GC)

Summary

To investigate the efficacy of SHR-1701 combined with Rivoceranib, with or without SHR-2554, in patients with gastric or gastroesophageal junction adenocarcinoma who have progressed on or were intolerant to first-line immunotherapy-containing treatment

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests a combination of drugs — SHR-1701 (a dual immunotherapy drug), rivoceranib (an anti-angiogenesis drug that cuts off blood supply to tumours), with or without SHR-2554 — in patients with advanced stomach or gastroesophageal cancer who have already received immunotherapy as their first treatment but whose cancer kept progressing. **You may be eligible if...** - You are 18 or older - You have confirmed stomach or gastroesophageal junction cancer - Your cancer progressed on or you could not tolerate a prior treatment that included an immune checkpoint inhibitor - Your cancer is HER2-negative - You are willing to provide tumour tissue samples for biomarker testing **You may NOT be eligible if...** - Your cancer is HER2-positive - You have not yet received any immunotherapy - You have serious other health conditions that prevent study participation Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSHR-1701+Rivoceranib + SHR-2554

Drug: SHR-1701 Administered by intravenous (IV) infusion on Day 1 of each 21-day cycle. The infusion time should be controlled between 30 and 60 minutes, and must not exceed 2 hours. Drug: Rivoceranib Administered orally (PO) once daily (QD), continuously. Administration Instructions: To be taken orally with warm water, approximately 30 minutes after a meal. The daily dosing time should be consistent. Drug: SHR-2554 Administered orally (PO) twice daily (BID). Administration Instructions: Can be taken before or after meals, but administration approximately 30 minutes after morning and evening meals is recommended. The daily dosing times should be consistent.

DRUGSHR-1701 + Rivoceranib

Locations(1)

Liaoning Provincial Cancer Hospital

Shenyang, Liaoning, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07311408

Related Trials

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

NCT06764875293 locations

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

NCT0678917210 locations

THE-0504 in Patients With Solid Tumors

NCT076461061 location

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

NCT062652851 location

A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment

NCT075181471 location